Patient Health Questionnaire Somatic Symptom Severity Scale (PHQ-15)

1. Abstract

The Patient Health Questionnaire Somatic Symptom Severity Scale (PHQ-15) is a standardized, self-administered psychometric instrument engineered to quantify somatic symptom burden and facilitate screening for somatic symptom disorder and related somatoform conditions in adult populations. Derived from the comprehensive Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Health Questionnaire (PHQ), the instrument operationalizes the measurement of 15 high-prevalence physical complaints that account for an overwhelming majority of symptomatic presentations in primary care, occupational health, and general medical environments. These complaints span multiple physiological domains, including musculoskeletal pain, gastrointestinal dysfunction, cardiopulmonary and autonomic reactivity, functional neurological manifestations, and neurovegetative exhaustion. Each item queries the degree of symptom-related bother experienced over a retrospective recall frame of the preceding four weeks using an authentic 3-point ordinal scale scored from 0 (“Not bothered at all”) to 2 (“Bothered a lot”), yielding an overall cumulative metric ranging from 0 to 30. Psychometric validation studies demonstrate robust empirical performance, characterized by strong internal consistency (Cronbach’s $\alpha$ typically spanning .80 to .87), favorable test-retest stability (intraclass correlation coefficient $ICC = .83$), and rigorous construct, convergent, and criterion-related validity. Cut-point thresholds of 5, 10, and 15 demarcate low, medium, and high somatic symptom severity, correlating monotonically with functional impairment, disability days, ambulatory healthcare utilization, and psychiatric comorbidity. The PHQ-15 remains one of the most widely deployed self-report somatic inventories internationally, playing an indispensable role in psychiatric epidemiology, psychosomatic medicine, and clinical outcome monitoring.

2. Keywords

PHQ-15, Patient Health Questionnaire, somatic symptom severity, somatization, somatic symptom disorder, bodily distress, psychometrics, primary care screening, medically unexplained symptoms, functional somatic syndromes, somatoform disorders

3. Authors

The PHQ-15 was developed by a team of clinical investigators and psychometricians at Columbia University and the Regenstrief Institute:

• Kurt Kroenke, MD — Professor of Medicine, Indiana University School of Medicine; Research Scientist, Regenstrief Institute, Inc., Indianapolis, Indiana, USA.
• Robert L. Spitzer, MD (1932–2015) — Professor of Psychiatry, Department of Psychiatry, Columbia University College of Physicians and Surgeons; New York State Psychiatric Institute, New York, New York, USA.
• Janet B. W. Williams, DSW — Professor Emerita of Clinical Psychiatric Social Work (in Psychiatry), Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA.

The scale was developed as part of the broader PRIME-MD Patient Health Questionnaire development project, an initiative funded through educational grants from Pfizer Inc., designed to transition clinician-administered psychiatric diagnostic interviews into efficient, patient-completed screening and monitoring tools.

4. Purpose

Somatic symptoms represent the single most common presentation within ambulatory medical practice. Epidemiological investigations demonstrate that more than 80% of individuals seeking primary medical consultations present with physical complaints, yet between 33% and 50% of these symptoms remain “medically unexplained” after comprehensive clinical workups. In patients suffering from elevated physical distress, symptoms frequently manifest across multiple organ systems, generating profound functional disability, psychological distress, and disproportionate utilization of healthcare resources. The primary objective of the Patient Health Questionnaire Somatic Symptom Severity Scale (PHQ-15) is to deliver a psychometrically rigorous, brief, and clinically actionable metric capable of quantifying this multiorgan somatic burden.

From an applied perspective, the PHQ-15 serves three primary functions across medical, psychiatric, and research settings:

1. Systematic Screening and Risk Stratification: In routine primary care, occupational, and specialty clinical environments, the PHQ-15 rapidly identifies patients experiencing high levels of somatic symptom distress who are at elevated risk for somatoform disorders, somatic symptom disorder (SSD) as defined in the DSM-5, or Bodily Distress Disorder (BDD) under ICD-11. By using empirically validated cut-points, clinicians can categorize patients into discrete severity tiers (minimal, low, medium, and high), facilitating targeted clinical interventions and preventing unnecessary, invasive diagnostic testing.
2. Dimensional Severity Measurement: Unlike categorical diagnostic interviews that merely establish the presence or absence of a disorder, the PHQ-15 evaluates the cumulative severity and subjective distress associated with bodily sensations. This dimensional approach is vital for tracking longitudinal trajectories, evaluating therapeutic responsiveness in clinical trials (e.g., pharmacotherapy, cognitive-behavioral therapy, or multidisciplinary pain rehabilitation), and monitoring changes across the continuum of care.
3. Epidemiological and Health Services Research: The PHQ-15 provides researchers with a standardized, cross-culturally validated instrument to assess the correlates of somatic distress. It facilitates investigations into the socioeconomic determinants of somatization, the comorbidity between physical distress and affective or anxiety disorders, health-related quality of life decrements, sickness absence, and direct/indirect healthcare expenditures.

The theoretical rationale for the PHQ-15 reflects a paradigm shift in psychosomatic medicine. Historic diagnostic frameworks (such as the DSM-III and DSM-IV) relied heavily on establishing whether a physical symptom was definitively “medically unexplained”—a dualistic dichotomy that was notoriously unreliable, clinically alienating, and philosophically problematic. In contrast, the PHQ-15 focuses directly on the subjective burden and distress produced by the symptoms, irrespective of their underlying etiology. This etiology-neutral measurement philosophy aligns seamlessly with modern psychiatric classifications, which prioritize patient-reported distress, symptom-focused worry, and behavioral disruption over organic-versus-psychogenic dualism.

5. Psychological Construct

The core psychological construct measured by the PHQ-15 is somatic symptom severity, defined as the cumulative self-reported burden, frequency, and personal distress caused by physical bodily complaints over a specified temporal window. Somatic symptom severity reflects an individual’s conscious awareness of bodily sensations coupled with an appraisal of those sensations as intrusive, disturbing, or incapacitating. Rather than assessing a solitary symptom in isolation, the PHQ-15 conceptualizes somatic distress as a multiorgan, cross-system phenomenon comprising several underlying physiological and experiential subdomains:

Pain Manifestations

Pain accounts for the largest proportion of items on the scale and represents the most debilitating dimension of somatic distress. The PHQ-15 indexes several anatomically distinct pain phenotypes:

• Musculoskeletal and Joint Pain: Assessed via Item 2 (Back pain) and Item 3 (Pain in your arms, legs, or joints). These complaints capture diffuse soft-tissue tension, chronic musculoskeletal strain, fibromyalgia-like syndromes, and regional biomechanical discomfort.
• Cephalic and Visceral Pain: Assessed via Item 1 (Stomach pain) and Item 5 (Headaches). These items evaluate recurrent gastrointestinal distress, tension-type headaches, migraine patterns, and visceral hypersensitivity.
• Reproductive/Urogenital Pain: Captured by Item 4 (Menstrual cramps or other problems with your periods) and Item 11 (Pain or problems during sexual intercourse), evaluating pelvic discomfort and sexual dysfunction associated with somatic sensitivity.

Gastrointestinal Dysregulation

Functional gastrointestinal symptoms are strongly correlated with psychological stress via the brain-gut-microbiome axis. Beyond abdominal pain, the PHQ-15 incorporates Item 12 (Constipation, loose bowels, or diarrhea) and Item 13 (Nausea, gas, or indigestion). These capture disturbances in motility, visceral perception, autonomic modulation of digestive secretions, and the cardinal features of irritable bowel syndrome and functional dyspepsia.

Cardiopulmonary and Autonomic Hyperarousal

Perceptions of cardiovascular and respiratory irregularity frequently reflect dysregulated autonomic feedback loops and hypervigilant interoception. The scale captures this domain through:

• Item 6: Chest pain — frequently a source of acute medical anxiety and panic-related presentation.
• Item 7: Dizziness — reflecting subjective lightheadedness, postural instability, or vestibular distress.
• Item 8: Fainting spells — indexing syncopal or presyncopal sensations.
• Item 9: Feeling your heart pound or race — capturing palpitations and sympathetic nervous system activation.
• Item 10: Shortness of breath — assessing dyspnea, hyperventilation, and thoracic constriction.

General Neurovegetative and Fatigue Manifestations

Chronic somatic distress is inextricably linked to systemic vitality and physiological homeostasis. Item 14 (Feeling tired or having low energy) and Item 15 (Trouble sleeping) evaluate exhaustion, lack of restorative sleep, and chronic fatigue. These neurovegetative complaints frequently co-occur with pain and autonomic arousal, forming a symptom cluster that amplifies overall disability.

Collectively, these 15 indicators do not function as isolated pathological markers; rather, they serve as convergent manifestations of a latent bodily distress construct. Whether arising from verified chronic medical illnesses (e.g., rheumatoid arthritis, diabetes), central sensitization syndromes (e.g., fibromyalgia, chronic fatigue syndrome), or primary psychiatric disorders (e.g., major depressive disorder, generalized anxiety disorder), the PHQ-15 captures the final common pathway of physical symptom burden as perceived by the individual.

6. Theoretical Framework

The construction and clinical deployment of the PHQ-15 are grounded in several interlinked theoretical models across psychopathology, health psychology, and cognitive neuroscience:

The Biopsychosocial Model

Formulated by George L. Engel, the biopsychosocial model posits that health, illness, and healthcare delivery can only be comprehended by examining biological, psychological, and social dimensions concurrently. The PHQ-15 operationalizes this framework by rejecting biological reductionism. It acknowledges that while physical symptoms have physiological correlates (such as peripheral nociceptive signaling, inflammatory cytokines, or altered neuroendocrine function), the severity of the experienced symptom is fundamentally modulated by psychological appraisal, affective state, and sociocultural context.

Cognitive-Behavioral and Somatosensory Amplification Models

Cognitive-behavioral models of somatization, pioneered by Arthur Barsky, David Mechanic, and Paul Salkovskis, emphasize the role of somatosensory amplification—the tendency to experience somatic sensations as intense, noxious, and threatening. According to this framework, individuals with elevated somatic symptom severity exhibit:

1. Interoceptive Hypervigilance: Selective attentional allocation toward benign physiological fluctuations (e.g., transient gastrointestinal borborygmi, sinus tachycardia, minor muscle twitches).
2. Catastrophic Cognitive Misinterpretation: Assigning sinister, life-threatening meanings to normal or benign bodily changes (e.g., interpreting transient thoracic tightness as an impending myocardial infarction).
3. Behavioral Reinforcement: Maladaptive coping strategies, such as bodily checking, avoidance of physical activity, and repeated medical reassurance seeking, which paradoxically exacerbate sensory gating deficits and perpetuate physical distress.

Negative Affectivity and the Symptom Perception Hypothesis

Extensive psychometric and experimental research by David Watson and James Pennebaker highlights the pervasive role of negative affectivity (neuroticism) in symptom reporting. Individuals with elevated negative affectivity possess a low threshold for experiencing physical discomfort and emotional distress. Consequently, the PHQ-15 reflects not only organ-specific pathophysiology but also the individual’s baseline dispositional vulnerability to perceive, amplify, and report physical sensations. This theoretical link explains the robust empirical correlations consistently observed between the PHQ-15 and measures of depression (such as the Beck Depression Inventory and the PHQ-9) and anxiety (such as the GAD-7).

Predictive Processing and Central Sensitization

Contemporary neurocomputational theories of psychosomatic medicine utilize the predictive coding framework (Karl Friston, Mark Edwards). In this model, the brain operates as a hierarchical predictive engine that generates top-down prior beliefs (“priors”) regarding incoming interoceptive sensations. In individuals with chronic somatic symptom disorders, these prior expectations of bodily disturbance become heavily weighted, overriding bottom-up sensory afferents. Coupled with central sensitization—a state of generalized neuronal hyperexcitability within nociceptive and autonomic processing networks—the central nervous system amplifies physiological noise into conscious, distressing pain and autonomic disturbance. The PHQ-15 functions as an indirect clinical readout of this amplified interoceptive inferencing.

7. Validity

The psychometric validity of the PHQ-15 has been extensively documented across diverse clinical populations, general community cohorts, and international healthcare settings.

Criterion and Diagnostic Validity

In the seminal validation study conducted by Kroenke, Spitzer, and Williams (2002) across 6,000 primary care and obstetrics-gynecology patients, increasing PHQ-15 scores demonstrated a profound, stepwise association with functional disability and healthcare utilization. Compared to patients in the minimal symptom group (scores 0–4), individuals with high somatic symptom severity (scores $ge 15$) exhibited:

• A 3.6-fold increase in self-reported physical disability days ($p < .001$).
• A 2.5-fold increase in physician clinic visits ($p < .001$).
• Significantly higher rates of symptom-related functional difficulty across home, work, and interpersonal domains.

When evaluated against structured psychiatric clinical interviews for DSM-IV somatoform disorders, the PHQ-15 displays robust diagnostic performance. Van Ravesteijn et al. (2009) evaluated the screening accuracy of the instrument in primary care, demonstrating that at an optimal cut-point of $ge 6$, the PHQ-15 achieved a sensitivity of 78% and a specificity of 71% for detecting any somatoform disorder. Crucially, the test yielded a negative predictive value of 97%, indicating that individuals scoring below 6 possess only a 3% probability of harboring an underlying somatoform diagnosis, confirming the scale’s power as an exclusionary screening tool.

Convergent and Discriminant Validity

Convergent validity has been established through substantial correlations with other validated psychometric scales. The PHQ-15 correlates strongly with:

• Physical component summary scores of the Medical Outcomes Study Short-Form Health Survey (SF-36; $r = -.50$ to $-.68$).
• Measures of depressive severity, including the Beck Depression Inventory (BDI; $r = .48$ to $.61$) and the PHQ-9 ($r = .55$ to $.65$).
• Measures of generalized psychological distress and anxiety, including the General Health Questionnaire (GHQ-12; $r = .45$ to $.58$) and the GAD-7 ($r = .52$ to $.62$).

Discriminant validity is supported by findings that, while PHQ-15 scores correlate moderately with depression and anxiety, exploratory and confirmatory factor analyses demonstrate that the somatic construct forms a distinct empirical factor that separates cleanly from cognitive-affective depressive symptoms (e.g., anhedonia, worthlessness, suicidal ideation) and psychological worry. Furthermore, multivariable regression models demonstrate that somatic symptom severity independently predicts functional disability, sickness absence, and medical utilization even after controlling for baseline depression, generalized anxiety, age, and chronic organic disease status (Kroenke et al., 2002, 2010).

Cross-Cultural and Population Invariance

The metric and structural validity of the PHQ-15 has been demonstrated across dozens of cultural and linguistic environments. In large-scale population standardizations, such as the German nationwide normative study by Kocalevent et al. (2013; $N = 5,031$), the scale exhibited stable normative distributions across age brackets and genders, although women consistently report higher somatic symptom severity across cultures. Studies conducted in East Asian cohorts, such as psychiatric and primary care outpatients in South Korea (Han et al., 2009) and Taiwan (Liao et al., 2016), confirmed excellent psychometric convergence, noting that somatic complaints frequently serve as the primary idiom of distress in Asian clinical encounters.

However, investigators have noted cross-cultural variations in Hispanic and Latino populations (Interian et al., 2006). Somatic symptom reporting among Hispanic primary care patients is frequently elevated due to cultural idioms such as ataques de nervios, variations in somatic attribution, and differences in healthcare-seeking thresholds. These findings emphasize the necessity of interpreting absolute cut-points within specific cultural contexts.

8. Reliability

The PHQ-15 has undergone extensive empirical evaluation regarding its classical test theory parameters, displaying consistently high levels of internal consistency and temporal stability across diverse clinical and non-clinical samples.

Internal Consistency

Across validation studies, the internal consistency of the PHQ-15, typically estimated via Cronbach’s coefficient alpha ($\alpha$) and McDonald’s omega ($\omega$), consistently meets or exceeds the conventional thresholds required for individual-level clinical assessment ($ge .80$):

• Original Validation Cohort (Kroenke et al., 2002): The instrument demonstrated a Cronbach’s $\alpha$ of .80 in an initial primary care sample ($N = 3,000$) and .79 in an obstetrics-gynecology validation sample ($N = 3,000$).
• General Population Samples: In a large, nationally representative German sample ($N = 5,031$), Kocalevent et al. (2013) reported an overall Cronbach’s $\alpha$ of .82, with female subgroups yielding $\alpha = .83$ and male subgroups yielding $\alpha = .80$.
• Psychiatric and Specialized Clinical Settings: In an outpatient psychiatric sample evaluated by Han et al. (2009), the Korean version of the PHQ-15 achieved an internal consistency of $\alpha = .87$. Similarly, de Vroege et al. (2012) confirmed $\alpha = .81$ in an occupational health setting.

Item-total correlations for individual symptoms generally range from .35 to .62. Symptoms such as fatigue, back pain, and headache routinely demonstrate the highest item-total correlations, whereas fainting spells and sexual difficulties exhibit lower, yet statistically significant, item-total correlations due to lower base rates in general outpatient populations.

Test-Retest Stability

Temporal stability over short intervals is critical for establishing that the instrument captures enduring somatic distress rather than acute, transient physiological states. Van Ravesteijn et al. (2009) evaluated the test-retest reliability of the PHQ-15 in a primary care cohort over a 2-week interval, obtaining an intraclass correlation coefficient (ICC) of 0.83 (95% CI: 0.77–0.88). In clinical trials where patients remained clinically stable on placebo, test-retest correlations spanning 4 to 6 weeks have consistently ranged between $r = .75$ and $.84$, demonstrating that the scale possesses adequate stability while retaining appropriate sensitivity to genuine clinical change following effective therapeutic interventions.

Standard Error of Measurement and Responsiveness

The Standard Error of Measurement (SEM) for the total score has been estimated across several studies between 1.5 and 2.1 points. Consequently, the Minimal Detectable Change (MDC) at the 95% confidence level is approximately 3.5 to 4.2 points. A longitudinal shift of 3 to 4 points on the cumulative scale represents a clinically meaningful change in somatic symptom distress rather than random measurement fluctuation.

9. Factor Analysis

The latent factorial architecture of the PHQ-15 has been the subject of extensive psychometric investigation utilizing both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA). These analyses examine whether somatic symptom severity is best conceptualized as a single unidimensional construct, a set of correlated organ-specific factors, or a hierarchical bifactor configuration.

Exploratory Factor Solutions

In the original structural exploration conducted by Kroenke and colleagues (2002), an unrotated principal components analysis revealed that the first factor accounted for a substantial proportion of the total variance, with all 15 items exhibiting positive factor loadings exceeding .30. This supported the clinical scoring convention of aggregating all items into a single composite index representing total somatic symptom severity.

Subsequent exploratory factor analyses implementing oblique rotations (e.g., Promax or Oblimin) across independent primary care and general population cohorts consistently identify between three and four correlated sub-factors:

1. Pain/Musculoskeletal Factor: Characterized by high loadings from Item 2 (Back pain), Item 3 (Joint/limb pain), and Item 5 (Headaches).
2. Gastrointestinal Factor: Marked by dominant loadings from Item 1 (Stomach pain), Item 12 (Bowel irregularities), and Item 13 (Nausea, gas, indigestion).
3. Cardiopulmonary/Autonomic Factor: Dominated by Item 6 (Chest pain), Item 7 (Dizziness), Item 9 (Heart pounding/racing), and Item 10 (Shortness of breath).
4. Neurovegetative/Fatigue-Sleep Factor: Driven by Item 14 (Fatigue/low energy) and Item 15 (Trouble sleeping).

Confirmatory Factor Analysis and Structural Models

Multiple structural equation modeling studies have formally tested competing factor configurations. The typical models compared include:

• Model 1 (Strict Unidimensional Model): All 15 items load onto a solitary latent somatic distress dimension. While parsimonious, this model typically yields borderline fit indices in large samples (e.g., Comparative Fit Index [CFI] $\approx .88-.91$; Root Mean Square Error of Approximation [RMSEA] $\approx .07-.08$).
• Model 2 (Correlated 4-Factor Model): Items load onto distinct, correlated latent factors (Pain, GI, Cardiopulmonary, Fatigue). This structure demonstrates significantly improved fit (CFI $\approx .94-.96$; Tucker-Lewis Index [TLI] $\approx .93-.95$; RMSEA $\approx .04-.05$).
• Model 3 (Bifactor Model): Every item loads onto a single, overarching general somatic distress factor ($G$), while simultaneously loading onto orthogonal, symptom-specific group factors ($S_1$ to $S_4$).

Across numerous rigorous CFA investigations (e.g., Kocalevent et al., 2013; Liao et al., 2016), the bifactor model consistently demonstrates the superior psychometric fit to the data, yielding fit indices characterized by $\chi^2/df < 2.5$, CFI $ge .96$, TLI $ge .95$, and RMSEA $le .04$. Calculation of the Explained Common Variance (ECV) and the omega hierarchical coefficient ($\omega_h$) in these bifactor models demonstrates that the general somatic factor accounts for more than 70% to 75% of the common variance across items. These findings provide rigorous empirical justification for the routine clinical practice of summing all 15 items into a single cumulative score: while multidimensional physiological facets exist, individual variance is primarily driven by a robust, overarching latent somatic symptom severity dimension.

10. Instrument / Measurement Tool

The structured attributes, administration protocols, and scoring mechanics of the instrument are detailed below:

• Instrument Name: Patient Health Questionnaire Somatic Symptom Severity Scale
• Acronym: PHQ-15
• Primary Developers: Kurt Kroenke, MD; Robert L. Spitzer, MD; Janet B. W. Williams, DSW
• Publication Year: 2002
• Measurement Paradigm: Classical Test Theory (CTT) self-report rating scale
• Target Population: Adults (aged 18 years and older); validated in adolescent samples down to age 12
• Clinical Settings: Primary care clinics, inpatient and outpatient hospital services, psychiatric consultations, occupational health screening, and epidemiological research
• Administration Mode: Self-administered (paper-and-pencil, computer, tablet, mobile application, or clinician-facilitated interview)
• Completion Time: Approximately 2 to 3 minutes
• Item Count: 15 items indexing somatic complaints across multiple anatomical systems
• Temporal Recall Window: The past 4 weeks (“During the past 4 weeks, how much have you been bothered by any of the following problems?”)
• Response Scale (Authentic 3-point ordinal scale):
  • 0 = Not bothered at all
  • 1 = Bothered a little
  • 2 = Bothered a lot
• Scoring Algorithm:
  • All 15 individual items are scored ordinally from 0 to 2.
  • The total PHQ-15 composite score is calculated as the sum of all item responses: $\text{Total Score} = \sum_{i=1}^{15} \text{Item}_i$.
  • Theoretical score range: 0 to 30 points.
• Gender Specificity Rule for Item 4:
  • Item 4 queries “Menstrual cramps or other problems with your periods” and is applicable only to female respondents.
  • In male respondents, Item 4 is coded as 0 (“Not bothered at all”) or omitted from administration.
  • When Item 4 is omitted for male respondents, researchers either retain the 0 score or apply a pro-rating formula: $\text{Pro-rated Score} = \left(\frac{\text{Raw Sum of 14 Items}}{14}\right) \times 15$. In routine clinical practice, coding Item 4 as 0 for men produces minimal classification error.
• Empirical Severity Thresholds:
  • 0 – 4: Minimal somatic symptom severity
  • 5 – 9: Low somatic symptom severity
  • 10 – 14: Medium somatic symptom severity
  • 15 – 30: High somatic symptom severity
• Diagnostic Screening Cut-Point:
  • A cut-point score of $ge 6$ or $ge 10$ is commonly utilized for somatoform / somatic symptom disorder screening. A score $ge 10$ offers optimal specificity in psychiatric and high-prevalence settings, whereas $ge 6$ maximizes screening sensitivity in general primary care.

11. Permissions & Fee and Test Year

The Patient Health Questionnaire Somatic Symptom Severity Scale (PHQ-15) was published in its validated form in 2002 by Kurt Kroenke, Robert L. Spitzer, and Janet B. W. Williams. The scale was developed under the auspices of the PRIME-MD development program, which received financial backing via educational grants from Pfizer Inc.

The PHQ-15 is in the public domain. In alignment with the developers’ commitment to advancing psychiatric assessment in global medical practice, the instrument is available free of charge for clinical practice, educational use, and academic research. No royalty payments, copyright fees, or formal licensing agreements are required to administer, score, or translate the instrument. Researchers and clinicians can freely access official copies of the PHQ-15 and its international language adaptations via the official distribution repository at www.phqscreeners.com.

While the scale is freely accessible, the developers require that the wording of the items and the response categories remain unaltered to preserve psychometric validity, and that proper academic attribution to the original authors (Kroenke, Spitzer, & Williams, 2002) be maintained in all published scientific works and clinical platforms.

12. References

The academic evidence and theoretical literature supporting the PHQ-15 are documented in the following peer-reviewed publications:

• American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425596
• Barsky, A. J., & Wyshak, G. (1990). Hypochondriasis and somatosensory amplification. British Journal of Psychiatry, 157(3), 404–409. https://doi.org/10.1192/bjp.157.3.404
• de Vroege, L., Hoedeman, R., Nuyen, J., Sijtsma, K., & van der Feltz-Cornelis, C. M. (2012). Validation of the PHQ-15 for somatoform disorder in the occupational health care setting. Journal of Occupational Rehabilitation, 22(4), 546–555. https://doi.org/10.1007/s10926-012-9366-0
• Han, C., Pae, C. U., Patkar, A. A., Masand, P. S., Kim, K. W., Joe, S. H., & Jung, I. K. (2009). Psychometric properties of the Patient Health Questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. Psychosomatics, 50(6), 580–585. https://doi.org/10.1016/s0033-3182(09)70859-x
• Interian, A., Allen, L. A., Gara, M. A., Escobar, J. I., & Díaz-Martínez, A. (2006). Somatic complaints in primary care: Further examining the validity of the Patient Health Questionnaire (PHQ-15). Psychosomatics, 47(5), 392–398. https://doi.org/10.1176/appi.psy.47.5.392
• Kocalevent, R. D., Hinz, A., & Brähler, E. (2013). Standardization of a screening instrument (PHQ-15) for somatization syndromes in the general population. BMC Psychiatry, 13(1), Article 91. https://doi.org/10.1186/1471-244X-13-91
• Kroenke, K., Spitzer, R. L., & Williams, J. B. (2002). The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine, 64(2), 258–266. https://doi.org/10.1097/00006842-200203000-00008
• Kroenke, K., Spitzer, R. L., Williams, J. B., & Löwe, B. (2010). The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: A systematic review. General Hospital Psychiatry, 32(4), 345–359. https://doi.org/10.1016/j.genhosppsych.2010.03.006
• Liao, S. C., Huang, W. L., Ma, H. M., Lee, M. T., Chen, T. T., Chen, I. M., & Gau, S. S. F. (2016). The relation between the Patient Health Questionnaire-15 and DSM somatic diagnoses. BMC Psychiatry, 16(1), Article 351. https://doi.org/10.1186/s12888-016-1068-2
• Spitzer, R. L., Kroenke, K., & Williams, J. B. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA, 282(18), 1737–1744. https://doi.org/10.1001/jama.282.18.1737
• van Ravesteijn, H., Wittkampf, K., Lucassen, P., van de Lisdonk, E., van den Hoogen, H., van Weert, H., Huijser, J., Schene, A., van Weel, C., & Speckens, A. (2009). Detecting somatoform disorders in primary care with the PHQ-15. The Annals of Family Medicine, 7(3), 232–238. https://doi.org/10.1370/afm.985
• Watson, D., & Pennebaker, J. W. (1989). Health complaints, stress, and distress: Exploring the central role of negative affectivity. Psychological Review, 96(2), 234–254. https://doi.org/10.1037/0033-295X.96.2.234

13. Items of the Scale